OBM Transplantation (ISSN 2577-5820) is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc., which covers all evidence-based scientific studies related to transplantation, including: transplantation procedures and the maintenance of transplanted tissues or organs; assimilation of grafted tissue and the reconstitution of removed organs or parts of organs; transplantation of heart, lung, kidney, liver, pancreatic islets and bone marrow, etc. Areas related to clinical and experimental transplantation are also of interest.

OBM Transplantation is committed to rapid review and publication, and we aim at serving the international transplant community with high accessibility as well as relevant and high quality content.

We welcome original clinical studies as well as basic science, reviews, short reports/rapid communications, case reports, opinions, technical notes, book reviews as well as letters to the editor. 


Publication Speed (median values for papers published in 2023): Submission to First Decision: 6.7 weeks; Submission to Acceptance: 14.4 weeks; Acceptance to Publication: 6 days (1-2 days of FREE language polishing included)

Current Issue: 2024  Archive: 2023 2022 2021 2020 2019 2018 2017

Special Issue

Islet Cell Transplantation

Submission Deadline: January 15, 2021 (Open) Submit Now

Guest Editors

Kenneth L. Brayman, MD, PhD, FACS

Professor of Surgery, Medicine and Biomedical Engineering, Director, Kidney, Pancreas and Islet Transplant Programs, Director, Center for Cellular Therapy and Biologic Theraputics, Department of Surgery, University of Virginia Health System, 1215 Lee Street, Charlottesville, VA 22908, USA

Website | E-Mail

Research Interests: Transplant immunosuppression; chronic allograft nephropathy; solid organ transplantation in patients with HIV; islet cell transplantation; transplantation tolerance; gene therapy and xenotransplantation; kidney transplantation; pancreas transplantationa

Preeti Chhabra, PhD

Department of Surgery, University of Virginia, Charlottesville, VA 22908, USA

Website | E-Mail

Research Interests: Type 1 diabetes; islet transplantation; inflammatory diseases; transplant immunosuppression; tolerance induction; regenerative medicine and immunoglobulin M therapy

About This Topic

This special issue primarily focuses on beta-cell replacement beyond islets alone, including isolated beta-cells, stem cells, encapsulated cells and xenotransplants. It covers all evidence-based preclinical and clinical research related to islet transplantation, i.e. transplantation procedures; graft survival and prevention of graft dysfunction and failure caused due to immune rejection and the recurrence of autoimmunity; the harmful side-effects of chronic immunosuppression; novel autoimmune and β-cell therapies that restore immune regulation and restore glucose control following islet transplantation; as well as financial and regulatory approval issues. It also invites articles on regeneration of functional insulin-producing beta cells for transplantation; encapsulation or immunoisolation of alternative beta-cell sources; and predictive or prognostic biomarkers that provide surrogate end points to determine the efficacy of islet transplantation. Last but not least, articles in the field of islet xenotransplantation are also invited.

Manuscript Submission Information

Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (transplantation@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.

Welcome your submission!


Open Access Review

The Future of Clinical Islet Transplantation in the United States

Received: 12 January 2021;  Published: 25 March 2021;  doi: 10.21926/obm.transplant.2101140


Clinical islet transplantation was first realized over four decades ago at the University of Minnesota. Autologous islet transplantation is now widely recognized as a treatment to prevent diabetes in patients after pancreas excision and is offered at major transplant centers throughout the United States and the world. Type 1 diabetes represent [...]
Open Access Review

The Roles of Collagen in Islet Transplantation

Received: 02 October 2020;  Published: 27 November 2020;  doi: 10.21926/obm.transplant.2004127


Islet transplantation is a cellular replacement therapy for severe diabetes mellitus. Although the clinical outcome of islet transplant has been improving, the transplant efficacy of this treatment is not superior to that of pancreatic organ transplantation, a similar transplant therapy. Various factors have been characterized as ‘islet [...]
Open Access Review

Current Assessment of Clinical Pancreatic Islet Allotransplantation

Received: 20 September 2020;  Published: 16 November 2020;  doi: 10.21926/obm.transplant.2004125


Clinical islet allotransplantation represents a minimally invasive, efficacious alternative to pancreas transplantation for restoring glycemic control and insulin independence in select patients with type 1 diabetes that is complicated by intractable impaired hypoglycemia awareness and/or severe hypoglycemic events refractory to stabilization [...]